Cargando…

End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study

OBJECTIVE: This study aimed to define the end-of-life (EOL) healthcare utilisation and its cost and determinants for cancer patients and to proactively inform related strategies in mainland China. DESIGN: A population-based retrospective study. SETTING AND PARTICIPANTS: Data from 894 cancer patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhong, Pan, Zijing, Zhang, Liang, He, Ruibo, Jiang, Shan, Xu, Chengzhong, Lu, Fangfang, Zhang, Pei, Li, Boyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528019/
https://www.ncbi.nlm.nih.gov/pubmed/30898830
http://dx.doi.org/10.1136/bmjopen-2018-026309
_version_ 1783420134345408512
author Li, Zhong
Pan, Zijing
Zhang, Liang
He, Ruibo
Jiang, Shan
Xu, Chengzhong
Lu, Fangfang
Zhang, Pei
Li, Boyang
author_facet Li, Zhong
Pan, Zijing
Zhang, Liang
He, Ruibo
Jiang, Shan
Xu, Chengzhong
Lu, Fangfang
Zhang, Pei
Li, Boyang
author_sort Li, Zhong
collection PubMed
description OBJECTIVE: This study aimed to define the end-of-life (EOL) healthcare utilisation and its cost and determinants for cancer patients and to proactively inform related strategies in mainland China. DESIGN: A population-based retrospective study. SETTING AND PARTICIPANTS: Data from 894 cancer patients were collected in urban Yichang, China from 01 July 2015 to 30 June 2017. OUTCOME MEASURES: Emergency department (ED) visits, outpatient and inpatient hospitalisation services, intensive care unit (ICU) admission and total costs were used as the main outcomes. RESULTS: In this study, 66.8% of the 894 patients were male, and the average age was 60.4 years. Among these patients, 37.6% died at home, and patients had an average of 4.86 outpatient services, 2.23 inpatient hospitalisation services and 1.44 ED visits. Additionally, 5.9% of these patients visited the ICU at least once. During the EOL periods, the costs in the last 6 months, 3 months, 1 month and 1 week were US$18 234, US$13 043, US$6349 and US$2085, respectively. The cost increased dramatically as death approached. The estimation results of generalised linear regression models showed that aggressive care substantially affected expenditure. Patients with Urban Employee Basic Medical Insurance spent more than those with Urban Resident-based Basic Medical Insurance or the New Rural Cooperative Medical Scheme. The place of death and the survival time are also risk factors for increased EOL cost. CONCLUSION: The findings suggested that the EOL cost for cancer patients is associated with aggressive care, insurance type and survival time. Timing palliative care is urgently needed to address ineffective and irrational healthcare utilisation and to reduce costs. ETHICS AND DISSEMINATION: This study was approved by the Ethics Committee of the Tongji Medical College, Huazhong University of Science and Technology (IORG No.: IORG0003571). All the data used in this study were de-identified.
format Online
Article
Text
id pubmed-6528019
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-65280192019-05-21 End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study Li, Zhong Pan, Zijing Zhang, Liang He, Ruibo Jiang, Shan Xu, Chengzhong Lu, Fangfang Zhang, Pei Li, Boyang BMJ Open Health Services Research OBJECTIVE: This study aimed to define the end-of-life (EOL) healthcare utilisation and its cost and determinants for cancer patients and to proactively inform related strategies in mainland China. DESIGN: A population-based retrospective study. SETTING AND PARTICIPANTS: Data from 894 cancer patients were collected in urban Yichang, China from 01 July 2015 to 30 June 2017. OUTCOME MEASURES: Emergency department (ED) visits, outpatient and inpatient hospitalisation services, intensive care unit (ICU) admission and total costs were used as the main outcomes. RESULTS: In this study, 66.8% of the 894 patients were male, and the average age was 60.4 years. Among these patients, 37.6% died at home, and patients had an average of 4.86 outpatient services, 2.23 inpatient hospitalisation services and 1.44 ED visits. Additionally, 5.9% of these patients visited the ICU at least once. During the EOL periods, the costs in the last 6 months, 3 months, 1 month and 1 week were US$18 234, US$13 043, US$6349 and US$2085, respectively. The cost increased dramatically as death approached. The estimation results of generalised linear regression models showed that aggressive care substantially affected expenditure. Patients with Urban Employee Basic Medical Insurance spent more than those with Urban Resident-based Basic Medical Insurance or the New Rural Cooperative Medical Scheme. The place of death and the survival time are also risk factors for increased EOL cost. CONCLUSION: The findings suggested that the EOL cost for cancer patients is associated with aggressive care, insurance type and survival time. Timing palliative care is urgently needed to address ineffective and irrational healthcare utilisation and to reduce costs. ETHICS AND DISSEMINATION: This study was approved by the Ethics Committee of the Tongji Medical College, Huazhong University of Science and Technology (IORG No.: IORG0003571). All the data used in this study were de-identified. BMJ Publishing Group 2019-03-20 /pmc/articles/PMC6528019/ /pubmed/30898830 http://dx.doi.org/10.1136/bmjopen-2018-026309 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Health Services Research
Li, Zhong
Pan, Zijing
Zhang, Liang
He, Ruibo
Jiang, Shan
Xu, Chengzhong
Lu, Fangfang
Zhang, Pei
Li, Boyang
End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study
title End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study
title_full End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study
title_fullStr End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study
title_full_unstemmed End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study
title_short End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study
title_sort end-of-life cost and its determinants for cancer patients in urban china: a population-based retrospective study
topic Health Services Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528019/
https://www.ncbi.nlm.nih.gov/pubmed/30898830
http://dx.doi.org/10.1136/bmjopen-2018-026309
work_keys_str_mv AT lizhong endoflifecostanditsdeterminantsforcancerpatientsinurbanchinaapopulationbasedretrospectivestudy
AT panzijing endoflifecostanditsdeterminantsforcancerpatientsinurbanchinaapopulationbasedretrospectivestudy
AT zhangliang endoflifecostanditsdeterminantsforcancerpatientsinurbanchinaapopulationbasedretrospectivestudy
AT heruibo endoflifecostanditsdeterminantsforcancerpatientsinurbanchinaapopulationbasedretrospectivestudy
AT jiangshan endoflifecostanditsdeterminantsforcancerpatientsinurbanchinaapopulationbasedretrospectivestudy
AT xuchengzhong endoflifecostanditsdeterminantsforcancerpatientsinurbanchinaapopulationbasedretrospectivestudy
AT lufangfang endoflifecostanditsdeterminantsforcancerpatientsinurbanchinaapopulationbasedretrospectivestudy
AT zhangpei endoflifecostanditsdeterminantsforcancerpatientsinurbanchinaapopulationbasedretrospectivestudy
AT liboyang endoflifecostanditsdeterminantsforcancerpatientsinurbanchinaapopulationbasedretrospectivestudy